Alumis Inc. focuses on TYK2 inhibitors ESK-001 and A-005, with ESK-001 in Phase 3 for plaque psoriasis. Find out why ALMS ...
© 2025 American Heart Association, Inc. Departments of Surgery (T.M.B., J.M., J.S., S.B., K.A.G.), University of Michigan, Ann Arbor. Departments of Surgery (T.M.B ...
Additionally, the expression of phosphorylated IGF-1 receptor, AKT, and ERK ... in high-fat diet mice suppressed prostate cancer growth via the IGF-1 signaling pathway. Next, we investigated the ...
Sycume blocks the activation of IGF-1R signaling pathway mediated by IGF-1 and related ligands or agonistic antibodies, reducing the expression of downstream inflammatory factors. This inhibition ...
The PI3K/AKT/mTOR (PAM) signaling pathway is a classical pathway that is aberrantly activated in cancer cells and promotes the tumorigenesis, metastasis, resistance to castration therapy, ...
As China's first and the world's second approved IGF-1R antibody drug, SYCUME ® has ended a 70-year drought of no new treatment option for TED in China. This groundbreaking therapy will redefine the ...
SYCUME® blocks the activation of IGF-1R signaling pathway mediated by IGF-1 and related ligands or agonistic antibodies, reducing the expression of downstream inflammatory factors. This ...
As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China. This groundbreaking therapy will redefine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback